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Conclusions: The implementation of TID permits to take decisions 
about the system weakness. In the PC the adopted measures, after 
the analysis of TID,decrease the APD, and thus improve the outcome 
with similar acute effects.  
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Purpose/Objective: Incident management is an important aspect of 
risk management and quality assurance in the field of radiation 
therapy. Traditionally, actual incidents (AIs) that impact the patient 
and near misses (NMs) that are detected prior to reaching the patient 
have been analyzed and managed in a similar manner. This study aims 
to determine if AIs and NMs share similar characteristics and can be 
used interchangeably for risk assessment and continuous quality 
improvement. 
Materials and Methods: Safety reports submitted between January 
2010 and June 2012 at a Canadian radiotherapy centre were classified 
based on guidelines from the World Health Organization as follows: 
Incident nature (AI, NM), incident type (equipment, documentation, 
process) and stage of origin (booking/simulation, planning, treatment 
delivery). Incident type and stage of origin were compared between 
AIs and NMs. 
Results: Among the 552 cases retrieved, 25% were classified as AIs and 
75% as NMs. There were significant differences in the distribution of 
incident type (p<0.001) and stage of origin (p<0.001) between AIs and 
NMs. AIs were more likely to involve equipment errors (34% vs 8%), 
whereas NMs were more likely to involve documentation errors (42% 
vs. 9%). The majority of AIs originated at the treatment delivery stage 
(51%), while the majority of NMs originated at the booking/simulation 
stage (52%). Cross tabulation of the data revealed other interesting 
patterns. Process errors were the most common type of incident in 
both groups (AI 56%, NM 51%) but the stage of origin differed. For AIs, 
the majority of process errors occurred at the treatment delivery 
stage (48%) compared to the booking/simulation stage for NMs (56%). 
Similarly, while a comparable proportion of AIs and NMs originated at 
the planning stage, the majority of AIs were process errors (74%) while 
most of the NMs were documentation errors (54%). 
 
 
Conclusions: In this study, NMs were found to have different 
characteristics than AIs. The traditional practice of analyzing and 
managing NMs and AIs in a similar manner is not the optimal approach 
to managing risk in radiotherapy, as NMs may reflect different failure 
modes than AIs. NMs and AIs should be analyzed separately to identify 
important opportunities for quality improvement. 
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Purpose/Objective: ARISTOTLE is a UK NCRI phase III trial comparing 
standard versus novel chemo-radiotherapy as pre-operative treatment 
for MRI defined locally advanced rectal cancer. The pre-trial 
radiotherapy quality assurance (RTQA) process for ARISTOTLE is aimed 
at ensuring that participating centres comply with the outlining, 
planning and reporting standards required by the trial protocol. This 
paper summarises the initial results from the pre-trial RTQA 
assessments for participating centres. 
Materials and Methods: The main requirements of the pre-trial QA 
process are trial questionnaires, outlining and planning benchmark 
cases, process document and case submission. Specific aspects include 
the following.  Outlining Exercise. A reference CT dataset is provided 
for outlining. Participants are required to outline adhering to protocol 
and utilising naming conventions. It is a requirement that each RT 
centre returns at least one outlining benchmark case, reviewed and 
approved by the local Principal Investigator.  Planning Cases. Two 
planning benchmark cases are supplied, with volumes pre-delineated – 
one prone and one supine. Centres are requested to plan the example 
relating to the position they intend to use for trial patients. Planning 
is required to be performed as per protocol, with attention paid to 
the dose volume objectives for both target coverage and maximum 
patient doses. Planning QA includes submission and evaluation of a 
Plan Assessment Form using standardised metrics for reporting, which 
is completed and returned for the planning case. 
Results: Forty UK radiotherapy centres have participated in the QA 
process so far, with full QA completed for 32. Some centres returned 
planning cases from more than one clinician. The total number of 
cases returned to date is 40. Reports were submitted to participating 
centres when QA was completed, with specific dialogue to clarify and 
address points of uncertainty. Initial review of QA reports received to 
date suggests some evidence of protocol mis-interpretation with 
respect to the following. 
Outlining. Ipsilateral obturator internus (required to be outlined 
within CTV by protocol) not included by 11 clinicians of the 40 who 
have submitted to date. The contralateral obturator internus (not 
required to be outlined within CTV by protocol) was included by 5 
clinicians.  
  Group A Group B 
Age (years)  68.1 67.2 
Low risk PC (%)  10.3 25.0 
Medium risk PC (%) 44.8 27.8 
High Risk PC (%)  44.9 47.2 
APD (days)  6.4 (5.2, 7.5) 4.7 (3.4, 5.9) 
PAE (%) Grade 0  50.0 27.0 
PAE (%) Grade 1  34.5 54.1 
PAE (%) Grade 2  12.1 16.2 
PAE (%) Grade 3  3.4 2.7 
Estimated BF (%)   5.5 4.0  
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Planning. No systematic non-conformances with dose-volume and 
planning requirements have been observed from the responses to 
date, but some deviations from the required dose reporting protocol 
were found in returns from 10 of the 32 reporting centres.  
Conclusions: The pre-trial RTQA undertaken to date has highlighted 
some issues in outlining and planning but appropriate dialogue 
between the RTQA team and the participating centres has allowed 
these issues to be addressed. Thus the overall aim of compliance with 
protocol for all participating centres should be achievable. An on-trial 
QA process will also help support this requirement and is ongoing.  
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Purpose/Objective: The IAEA has along-standing history providing 
support and assistance for radiotherapy dosimetry audits in various 
countries. It has supported the development of methodology and 
establishment of several national TLD-based QA audit networks for 
radiotherapy dosimetry. The main objective was to extend the 
availability of radiotherapy dosimetry audits to as many radiotherapy 
centres as possible throughout the world. 
Materials and Methods: A series of Co-ordinated Research Projects 
(CRPs) has been conducted by the IAEA as of 1995 to assist in 
developing such national dosimetry audit programmes. The overall 
radiotherapy dosimetry audit approach established and developed 
throughout these CRPs is based on a process of increasingly complex 
steps and parameters being checked. The first CRP focused on the 
basic beam calibration audits. The basic programme was extended to 
audits in non-reference conditions through a second CRP. The third 
CRP concluded in 2012, has expanded the dosimetry audit tools for 
more complex techniques used for treatment of cancer patients. This 
approach was developed so that experience of previous levels is used 
to inform development, implementation and analysis of results for 
subsequent levels. 
Results: New procedures have been developed that include TLD based 
dosimetry for irregular fields, for heterogeneous situations, and for 
small MLC shaped fields relevant to stereotactic radiosurgery and 
applicable to dosimetry for IMRT. In addition the programme included 
a new development of film-based 2D dosimetry methodology for 
testing dose distributions in small field geometry. The IAEA Dosimetry 
Laboratory has actively participated in the experimental part of these 
CRPs, provided new phantoms and conducted multicentre pilot studies 
to test the newly developed methodology. The national audit 
networks participating in these CRPs have incorporated in their 
programmes procedures for auditing hospital dosimetry for these 
techniques. In addition, the IAEA contributes to strengthening QA of 
the national TLD systemsby exchanging dosimeters and verifying the 
TLD work of the national auditing organizations.  
Conclusions: Through the link with the IAEA Dosimetry Laboratory, 
the national audit networks closely cooperate at the consecutive 
stages of developing the dosimetry audit methodology locally and by 
carrying out cross-measurements. In this way the national audit 
systems are interlinked to ensure that international and national 
radiotherapy dosimetry audit networks are working to the consistent 
levels and standards. When broadly implemented, the network of 
national audit groups for radiotherapy dosimetry will contribute to 
ensuring the consistency of quality in dosimetry in radiotherapy 
centres world-wide.  
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Purpose/Objective: The purpose was to develop a mailed audit 
dosimetry system that takes into account influences from the whole 
treatment chain including CT scanning, treatment planning and 
treatment delivery. The purpose was also to use the audit system in 
our healthcare region to verify the quality of head and neck 
radiotherapy at the four included clinics. 
Materials and Methods: A semi-anthropomorphic phantom was 
constructed, designed to mimic the head and neck region. The 
phantom was made of PMMA, including a tumour structure partially 
encompassing the spinal column (made of Teflon), two structures 
resembling salivary glands, and a small air cavity symbolising the 
trachea. PMMA rods containing lithium formate EPR (electron 
paramagnetic resonance) dosimeters were inserted at six different 
measurement points in the phantom, three in the target volume,one 
in each salivary gland and one in medulla. The phantom was sent by 
mail to the audit sites where it was treated as a patient; including CT 
scan, dose planning and treatment delivery. A conventional five-field 
dose plan was used. After a complete treatment, the phantom was 
sent back together with the absorbed doses reported by the treatment 
planning system.  
Results: Audit measurements have been performed at all four clinics 
in the health care region, results are seen in figure 1. 
 
 
Figure 1. Results from audit measurements showing the deviation (in 
percent) between measured and calculated absorbed dose in the six 
different measurement points.  
Except for one clinic, all target and medulla measurement points 
agree within 1.5% between measured and calculated doses. The result 
for the two salivary glands shows a larger deviation, mainly because of 
the steep dose gradient over these structures. One clinic (triangle) is 
deviating compared to the other clinics. After additional 
measurements, the most likely explanation is a handling mistake. 
Within these clinics there are three different dose planning systems in 
use: pencil beam convolution, anisotropic analytic algorithm and 
collapsed cone. No significant difference can be seen between the 
different algorithms. The mailing procedure worked satisfying and the 
stability of the dosimeters was not affected by the transport. 
Conclusions: We find that the elaborated system provides a useful 
tool to ensure the quality of the radiotherapy treatments delivered in 
a clinic, especially when introducing new treatment modalities. The 
need for comprehensive and explicit audit instructions was found to 
be important. Our future plans are to use the audit system for 
IMRTand/or VMAT audits in the region and in the extension perform a 
national audit. 
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Purpose/Objective: Brand-new vertical layout type of small proton 
therapy system (PTS) has been developed. The first system has been 
installed at Aizawa Hospital in Japan since April 2012. Beam 
performance test is now underway.  
Materials and Methods: The world's first system which arranges 
compact rotating gantry and cyclotron in vertical direction has been 
developed to save space and cost of facility building. This system 
enables building space to be a half of that of the conventional type, 
and it makes PTS easier to be installed in a small area. Though the 
system becomes compact, its performance has been perfectly kept by 
using many state-of-the-art technologies. These are multi-purpose 
nozzle which has function of both wobbling and scanning irradiation, 
